Dr John Bridgewater
Dr Bridgewater is a Clinical Researcher at the UCL Cancer Institute. He trained in medicine at Oxford and University College London, and specialised in Medical Oncology at the Middlesex, Mount Vernon and Royal Marsden Hospitals. He holds a PhD in gene therapy from the Institute of Cancer Research. Dr Bridgewater leads the National Cancer Research Institute subgroup in hepatobiliary malignancy, and has a laboratory programme at the UCL Cancer Institute investigating carcinoma of unknown primary origin. He has participated in a number of landmark studies in GI malignancy and was senior author on the seminal publication in advanced biliary tract cancer, the ABC-02 study. He is chief and co-chief investigator on 3 lead studies in the NCRI upper GI portfolio and serves on a number of committees including those for the NCRI (UGI and colorectal), CTAAC and NICE.
Clinical gastrointestinal cancer research
Dr Bridgewater is chief investigator for the ABC-04 study, a phase 1b study of AZD6244 or Selumitinib with Cisplatin and Gemcitabine in biliary tract cancer. This is a lead study in the NCRI hepatobiliary portfolio which he leads and coordinates. He has developed an international collaboration of biliary tract investigators, essential for future studies. He is also co-chief investigator for the BILCAP (adjuvant treatment in biliary tract cancer), EPOC-B and New EPOC (neoadjuvant treatment for colorectal liver metastases). In addition he is on the trial management groups of the SCOPE (chemoradiation in oesophagogastric cancer) and SCALOP (chemoradiation in pancreatic cancer). He directs the translational programmes for these studies through multiple collaborations in progress. The blood and tissue banks developed represent a unique resource of material in the context of patients in clinical trials run to GCP standard. Dr Bridgewater continues to contribute to the NCRI GI portfolio and is consistently the highest recruiter into a number of studies.
Carcinoma of unknown primary
Dr Bridgewater leads a laboratory and clinical programme in carcinoma of unknown primary (CUP). The central hypothesis is the value of molecular diagnosis for CUP both in laboratory and clinical practice. This work has involved the investigation of mRNA, microRNA and methylation signatures and a clinical trial to determine the utility of molecular diagnosis. The core of this work has involved the investigation of molecular signatures from a cohort of patients with true CUP. This work is part of collaborations completed and continuing with Agendia, Manuel Esteller and Rosetta Genomics. He also leads the clinical service for CUP in the Integrated London Cancer Consortium.
Dr John Bridgewater
University College London Cancer Institute, London, UK
- Thierry André, Corrado Boni, Lamia Mounedji-Boudiaf, Mathilde Navarro, Josep Tabernero, Thamas Hickish, Clare Topham, Marta Zaninelli, Philip Clingan, John Bridgewater, Isabelle Tabah-Fisch, Aimery de Gramont. Oxaliplatin, 5 Fluorouracil and Leucovorin in Adjuvant Colon Cancer: Results of the International Randomized MOSAIC Trial. New Eng J Med 2004 Jun 3;350(23):2343-51
- Bridgewater J R van Laar R A Floore A and Van’t Veer L. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. Br J Cancer (2008) 98, 1425 – 1430
- Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira S, Roughton M, Bridgewater J. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N Engl J Med 2010;362:1273-81.
- Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2011 Jun 27.
- Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011 Jun 18;377(9783):2103-14.
- Fernandez AF, Assenov Y, Martin-Subero J, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, Monk D, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C, Esteller M. A DNA methylation fingerprint of 1,628 human samples. Genome Res. 2011 May 25.
- Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011.